1 Pharmacokinetic parameters of trapidil (an antagonist of platelet derived growth factor) were evaluated in 12 healthy male subjects (study I) and in a group of 10 patients with liver cirrhosis (Child B) and five control subjects, respectively (study II). 2 Investigations were carried out after a single dose trapidil (200 mg) and at steady state after application of 200 mg trapidil three times daily for 5 days (study 1) or 4 days (study II ). 3 Study I: The concentration-time curves of the terminal elimination phase of trapidil exhibited a slight convexity which might reflect nonlinear kinetics. Table 2. ated to desethyltrapidil which has similar, but about 10-fold weaker pharmacological properties with respect to platelet aggregation [ 11]. CYP450 isozymes involved in the degradation of trapidil have not yet been Investigations determined. This paper comprises the first studies reported on the single dose and steady state pharmacoStudy I. On day 1, plasma samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h after kinetics of trapidil in healthy subjects and in patients with impaired liver function.application of a single dose (capsule) containing 200 mg trapidil. From day 2 to day 4, trapidil was administered 200 mg three times daily. On day 5, after application of a last single dose (200 mg) of trapidil plasma samples were drawn as on day 1. On each of the pharmacokinetic Methods study days (i.e. days 1 and 5 ), trapidil intake followed an overnight fast, and a standardized breakfast was Study I was performed to investigate the pharmacokinetics of trapidil in 12 healthy male subjects after a served after 2 h. 200 mg single dose given on day 1 and day 5 following 200 mg three times daily trapidil during days 2 to 4. Study II. Investigations followed the same schedule as in study I, except there was a shorter treatment period Study II was carried out to assess the pharmacokinetics of trapidil in 10 patients with liver cirrhosis and five (3 instead of 4 days) and an additional blood sample was drawn 36 h after the last drug intake on day 4. age-matched subjects without liver disease after a 200 mg single dose given on day 1 and day 4 following 200 mg three times daily trapidil during days 2 and 3. The shorter treatment period in study II-carried out in T rapidil assay in-house patients -was due to logistic reasons.Trapidil and desethyltrapidil (M1) were determined in plasma by an h.p.l.c.-method and u.v.-detection. Lower limit of quantification (LLQ) was 0.004 mg ml−1 for Subject selection and study protocol trapidil, linearity was proven up to 16 mg ml−1. For M1, LLQ was 0.001mg ml−1 and linearity was obtained Both studies were approved by the Institutional Review Board of the Frankfurt University Hospital, and study within 0.001 and 5 mg ml−1. Samples containing higher concentrations were re-analysed after dilution. Day-tosubjects gave their written informed consent.Subjects in study I had a mean age of 29 years (range day variability was below 5%. 26-35 years), mean weight was 77 kg (range...